Metabolic impact of low dose IL-2 therapy for primary Sjögren’s Syndrome in a double-blind, randomized clinical trial
ClinicalTrials.gov number, NCT02464319. Key Points • Metabolic alteration in pSS is significantly associated with Ld-IL2 therapy. • Metabolic changes correlate with variations in immune cell subsets, particularly Tregs. • Metabolic profiling could be a valuable tool in guiding Ld-IL2 therapy choices for pSS patients.
Authors
- Ruiling Feng (ORCID: https://orcid.org/0000-0003-1465-3259)
- Xian Xiao (ORCID: https://orcid.org/0009-0007-2718-4371)
- Yuebo Jin (ORCID: https://orcid.org/0000-0003-3379-8998)
- Gong Cheng (ORCID: https://orcid.org/0000-0002-6164-1501)
- Yifan Wang (ORCID: https://orcid.org/0000-0002-2512-3774)
- Jiali Chen (ORCID: https://orcid.org/0000-0001-7929-5136)
- Bo Huang (ORCID: https://orcid.org/0000-0001-7811-898X)
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
Publication Details
- Journal
- Clinical Rheumatology
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1007/s10067-024-07165-2
- Citations
- 7
- Primary Topic
- Salivary Gland Disorders and Functions
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- National Natural Science Foundation of China
- Key Technologies Research and Development Program